Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
HOLON, ISRAEL, March 8, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a f...
Study builds on clinical benefit reported in heavily pretreated MSS CRC patients with liver metastases treated with dual combination of COM701 and nivolumab Initial findings
Compugen Ltd. (NASDAQ:CGEN – Get Rating) – Equities research analysts at Jefferies Financial Group issued their Q1 2023 earnings per share (EPS) estimates for shares of Compugen in a research note issued to investors on Monday, February 27th. Jefferies Financial Group analyst C. Howerton expects that the biotechnology company will earn ($0.14) per share for […]
The company released its fourth-quarter and full-year results after the bell Monday.